Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro

Journal of Korean Medical Science

Volumn 22, Issue SUPPL., 2007, Pages

  Eun, Jung Choi ^a   Young, Mi Whang ^a   Seok, Jin Kim ^a   Hyun, Jin Kim ^b   Yeul, Hong Kim ^a,c  

^a Korea University College of Medicine   (South Korea)

^b Milton Academy   (United States)

^c Korea University College of Medicine   (South Korea)

Author keywords

Chemoprevention; Fenretinide; Non small cell lung carcinoma; Receptors; Retinoic acid; Retinoids

Indexed keywords

EID: 36148932935     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.s.s52     Document Type: Article

References (32)

1. Lotan R. Retinoids as modulators of tumor cells invasion and metastasis. Semin Cancer Biol 1991; 2: 197-208.
2. Hofmann SL. Retinoids - "differentiation agents" for cancer treatment and prevention. Am J Med Sci 1992; 304: 202-13.
3. McBurney MW, Costa S, Pratt MA. Retinoids and cancer: a basis for differentiation therapy. Cancer Invest 1993; 11: 590-8.
4. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 22441-6.
5. Lokshin A, Zhang H, Mayotte J, Lokshin M, Levitt ML. Early effects of retinoic acid on proliferation, differentiation and apoptosis in non-small cell lung cancer cell lines. Anticancer Res 1999; 19: 5251-4.
6. Treat J, Friedland D, Luginbuhl W, Meehan L, Gorman G, Miller W Jr, Bavaria J, Kaiser L. Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. Cancer Invest 1996; 14: 415-20.
7. Lippman SM, Hong WK. 13-cis-retinoic acid and cancer chemoprevention. J Natl Cancer Inst Monogr 1992: 111-5.
8. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93: 605-18.
9. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397-406.
10. Mernitz H, Smith DE, Zhu AX, Wang XD. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett 2006; 244: 101-8.
11. Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003; 95: 206-14.
12. Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydrox yphenyl)retinamide] sufficient for cancer therapy? Int J Cancer 2002; 100: 520-6.
13. Sabichi AL, Xu H, Fischer S, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Clifford JL. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 2003; 9: 4606-13.
14. Um SJ, Lee SY, Kim EJ, Han HS, Koh YM, Hong KJ, Sin HS, Park JS. Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett 2001; 174: 127-34.
15. Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F, Formelli F. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996; 65: 491-7.
16. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 2006; 25: 2785-94.
17. Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999; 59: 2493-8.
18. Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998; 4: 1345-55.
19. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003; 9: 2032-9.
20. Budman DR, Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anticancer Drugs 2004; 15: 877-81.
21. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 5: 2924-33.
22. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004; 10: 4249-53.
23. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimerg IW, Brown BW, Goepfert H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
24. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
25. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, Reed JC, Pierotti MA. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 1995; 85: 359-67.
26. Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnaghi MI, Menard S. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 1995; 6: 863-9.
27. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6: 2973-9.
28. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-10.
29. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192: 1-15.
30. Holven KB, Natarajan V, Gundersen TE, Moskaug JO, Norum KR, Blomhoff R. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin. Int J Cancer 1997; 71: 654-9.
31. Lim SJ, Gutierrez-Puente Y, Tari AM. N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells. Tumour Biol 2002; 23: 279-86.
32. Formelli F, Cleris L. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur J Cancer 2000; 36: 2411-9.